Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinitech LaboratoryBOM:544220 -7.50%38 Quick Ratio is 5.86 as of Mar. 2026, which is 235% above its 10-year median of 1.75. GuruFocus rates BOM:544220 with a GF Score™ of 38/100. The stock has 6 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Clinitech Laboratory ranks better than 88.26% on this metric.
Clinitech Laboratory has a quick ratio of 5.86. It generally indicates good short-term financial strength.
The historical rank and industry rank for Clinitech Laboratory's Quick Ratio or its related term are showing as below:
BOM:544220'
s Quick Ratio Range Over the Past 10 Years
Min: 0.9 Med: 1.75 Max: 5.86
Current: 5.86
During the past 6 years, Clinitech Laboratory's highest Quick Ratio was 5.86. The lowest was 0.90. And the median was 1.75.
BOM:544220's Quick Ratio is ranked better than 88.26% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.79
vs BOM:544220: 5.86
Clinitech Laboratory (BOM:544220) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Clinitech Laboratory Quick Ratio Related Terms
Clinitech Laboratory Quick Ratio Historical Data
* Premium members only.
The historical data trend for Clinitech Laboratory's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544220 vs TMO, DHR, IDXX: Quick Ratio Comparison
For the Diagnostics & Research subindustry, Clinitech Laboratory's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinitech Laboratory Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinitech Laboratory's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Clinitech Laboratory's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Clinitech Laboratory's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinitech Laboratory (BOM:544220) has a Quick Ratio of 5.86 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Clinitech Laboratory and its competitors. This is 235% above median its historical median of 1.75. Over the past decade, Clinitech Laboratory's Quick Ratio has ranged from 0.90 to 5.86. According to the industry distribution chart, Clinitech Laboratory ranks #25 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 11.7%.
Is Clinitech Laboratory's Quick Ratio too high?
Clinitech Laboratory's current Quick Ratio of 5.86 is 235% above median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 5.86. The Medical Diagnostics & Research industry median Quick Ratio is 1.79. Clinitech Laboratory's value of 5.86 is 227.4% above this industry median. Based on the distribution chart, Clinitech Laboratory ranks #25 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Clinitech Laboratory has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Clinitech Laboratory's Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinitech Laboratory ranks #25 out of 213 companies for Quick Ratio. This places Clinitech Laboratory in the top 12% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.79. Clinitech Laboratory's value of 5.86 is 227.4% above this benchmark. Historically, Clinitech Laboratory's own Quick Ratio has ranged from 0.90 to 5.86 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 1.79, Clinitech Laboratory has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.79, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinitech Laboratory's current Quick Ratio of 5.86 is 227.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Clinitech Laboratory and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinitech Laboratory's current Quick Ratio is 5.86, which is 235% above median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinitech Laboratory stock overvalued right now?
Clinitech Laboratory (BOM:544220) has a current Quick Ratio of 5.86. The current Quick Ratio is 5.86, which is 235% above median its 10-year median of 1.75 and 227.4% above the Medical Diagnostics & Research industry median of 1.79. Clinitech Laboratory's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Clinitech Laboratory (BOM:544220), the current Quick Ratio is 5.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clinitech Laboratory Ltd is an Indian diagnostic and healthcare services provider company. It operates a network of diagnostic centers in Thane and Navi Mumbai and offers various medical tests across multiple specialties, including biochemistry, immunology, hematology, molecular biology, serology, microbiology, and histopathology. It serves individual patients as well as corporate clients, aiming to provide affordable and comprehensive diagnostic solutions.
38GF Score
Get the complete analysis for BOM:544220
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544220 has been successfully added to your 
